Cargando…
Human Pluripotent Stem Cells-Based Therapies for Neurodegenerative Diseases: Current Status and Challenges
Neurodegenerative diseases are characterized by irreversible cell damage, loss of neuronal cells and limited regeneration potential of the adult nervous system. Pluripotent stem cells are capable of differentiating into the multitude of cell types that compose the central and peripheral nervous syst...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7699962/ https://www.ncbi.nlm.nih.gov/pubmed/33233861 http://dx.doi.org/10.3390/cells9112517 |
_version_ | 1783616169525116928 |
---|---|
author | Ford, Elizabeth Pearlman, Jodie Ruan, Travis Manion, John Waller, Matthew Neely, Gregory G. Caron, Leslie |
author_facet | Ford, Elizabeth Pearlman, Jodie Ruan, Travis Manion, John Waller, Matthew Neely, Gregory G. Caron, Leslie |
author_sort | Ford, Elizabeth |
collection | PubMed |
description | Neurodegenerative diseases are characterized by irreversible cell damage, loss of neuronal cells and limited regeneration potential of the adult nervous system. Pluripotent stem cells are capable of differentiating into the multitude of cell types that compose the central and peripheral nervous systems and so have become the major focus of cell replacement therapies for the treatment of neurological disorders. Human embryonic stem cell (hESC) and human induced pluripotent stem cell (hiPSC)-derived cells have both been extensively studied as cell therapies in a wide range of neurodegenerative disease models in rodents and non-human primates, including Parkinson’s disease, stroke, epilepsy, spinal cord injury, Alzheimer’s disease, multiple sclerosis and pain. In this review, we discuss the latest progress made with stem cell therapies targeting these pathologies. We also evaluate the challenges in clinical application of human pluripotent stem cell (hPSC)-based therapies including risk of oncogenesis and tumor formation, immune rejection and difficulty in regeneration of the heterogeneous cell types composing the central nervous system. |
format | Online Article Text |
id | pubmed-7699962 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-76999622020-11-29 Human Pluripotent Stem Cells-Based Therapies for Neurodegenerative Diseases: Current Status and Challenges Ford, Elizabeth Pearlman, Jodie Ruan, Travis Manion, John Waller, Matthew Neely, Gregory G. Caron, Leslie Cells Review Neurodegenerative diseases are characterized by irreversible cell damage, loss of neuronal cells and limited regeneration potential of the adult nervous system. Pluripotent stem cells are capable of differentiating into the multitude of cell types that compose the central and peripheral nervous systems and so have become the major focus of cell replacement therapies for the treatment of neurological disorders. Human embryonic stem cell (hESC) and human induced pluripotent stem cell (hiPSC)-derived cells have both been extensively studied as cell therapies in a wide range of neurodegenerative disease models in rodents and non-human primates, including Parkinson’s disease, stroke, epilepsy, spinal cord injury, Alzheimer’s disease, multiple sclerosis and pain. In this review, we discuss the latest progress made with stem cell therapies targeting these pathologies. We also evaluate the challenges in clinical application of human pluripotent stem cell (hPSC)-based therapies including risk of oncogenesis and tumor formation, immune rejection and difficulty in regeneration of the heterogeneous cell types composing the central nervous system. MDPI 2020-11-20 /pmc/articles/PMC7699962/ /pubmed/33233861 http://dx.doi.org/10.3390/cells9112517 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Ford, Elizabeth Pearlman, Jodie Ruan, Travis Manion, John Waller, Matthew Neely, Gregory G. Caron, Leslie Human Pluripotent Stem Cells-Based Therapies for Neurodegenerative Diseases: Current Status and Challenges |
title | Human Pluripotent Stem Cells-Based Therapies for Neurodegenerative Diseases: Current Status and Challenges |
title_full | Human Pluripotent Stem Cells-Based Therapies for Neurodegenerative Diseases: Current Status and Challenges |
title_fullStr | Human Pluripotent Stem Cells-Based Therapies for Neurodegenerative Diseases: Current Status and Challenges |
title_full_unstemmed | Human Pluripotent Stem Cells-Based Therapies for Neurodegenerative Diseases: Current Status and Challenges |
title_short | Human Pluripotent Stem Cells-Based Therapies for Neurodegenerative Diseases: Current Status and Challenges |
title_sort | human pluripotent stem cells-based therapies for neurodegenerative diseases: current status and challenges |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7699962/ https://www.ncbi.nlm.nih.gov/pubmed/33233861 http://dx.doi.org/10.3390/cells9112517 |
work_keys_str_mv | AT fordelizabeth humanpluripotentstemcellsbasedtherapiesforneurodegenerativediseasescurrentstatusandchallenges AT pearlmanjodie humanpluripotentstemcellsbasedtherapiesforneurodegenerativediseasescurrentstatusandchallenges AT ruantravis humanpluripotentstemcellsbasedtherapiesforneurodegenerativediseasescurrentstatusandchallenges AT manionjohn humanpluripotentstemcellsbasedtherapiesforneurodegenerativediseasescurrentstatusandchallenges AT wallermatthew humanpluripotentstemcellsbasedtherapiesforneurodegenerativediseasescurrentstatusandchallenges AT neelygregoryg humanpluripotentstemcellsbasedtherapiesforneurodegenerativediseasescurrentstatusandchallenges AT caronleslie humanpluripotentstemcellsbasedtherapiesforneurodegenerativediseasescurrentstatusandchallenges |